HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease.

Abstract
The epidemiology of infections with 5 human herpesviruses (HHVs) (HHV-6, HHV-7, HHV-8, varicella zoster virus [VZV], and Epstein-Barr virus [EBV]) was investigated during the first year after solid organ transplantation in 263 patients who received oral ganciclovir or valganciclovir prophylaxis. HHV-6B DNAemia was uncommon, HHV-6A DNAemia was not observed, and HHV-7 DNAemia was prevalent. HHV-6 and HHV-7 DNAemia were not significantly associated with cytomegalovirus (CMV) disease, although a trend toward higher incidence of CMV disease was observed in HHV-6 DNAemic patients. VZV and HHV-8 DNAemia were not detected. EBV infection was common, although incidence of high-level EBV DNAemia was low, especially in patients who received valganciclovir prophylaxis. EBV-related posttransplant lymphoproliferative disease was not observed up to 12 months after transplantation. Compared with historic data, data from the present study suggest that antiviral prophylaxis may lower the incidence, prevalence, or level of DNAemia for infection with HHV-6, HHV-8, VZV, and EBV but not for infection with HHV-7.
AuthorsRaymund R Razonable, Robert A Brown, Atul Humar, Emma Covington, Emma Alecock, Carlos V Paya, PV16000 Study Group
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 192 Issue 8 Pg. 1331-9 (Oct 15 2005) ISSN: 0022-1899 [Print] United States
PMID16170749 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • Viral Proteins
Topics
  • Antiviral Agents (therapeutic use)
  • Cytomegalovirus Infections (epidemiology, etiology)
  • Herpesviridae Infections (prevention & control)
  • Humans
  • Organ Transplantation (adverse effects)
  • Risk
  • Viral Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: